Jackob Moskovitz1, Consuelo Walss-Bass2, Dianne A Cruz3, Peter M Thompson3, Jenaqua Hairston1, Marco Bortolato1. 1. Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, USA. 2. Department of Psychiatry and Behavioral Science, School of Medicine, University of Texas Health Science Center, Houston, USA. 3. Southwest Brain Bank, Department of Psychiatry, School of Medicine, University of Texas Health Science Center, San Antonio, USA.
Abstract
AIMS: The enzyme catechol-O-methyltransferase (COMT) plays a primary role in the metabolism of catecholamine neurotransmitters and is implicated in the modulation of cognitive and emotional responses. The best characterized single nucleotide polymorphism (SNP) of the COMT gene consists of a valine (Val)-to-methionine (Met) substitution at codon 108/158. The Met-containing variant confers a marked reduction in COMT catalytic activity. We recently showed that the activity of recombinant COMT is positively regulated by the enzyme Met sulphoxide reductase (MSR), which counters the oxidation of Met residues of proteins. The current study was designed to assess whether brain COMT activity may be correlated to MSR in an allele-dependent fashion. METHODS: COMT and MSR activities were measured from post-mortem samples of prefrontal cortices, striata and cerebella of 32 subjects by using catechol and dabsyl-Met sulphoxide as substrates, respectively. Allelic discrimination of COMT Val(108/185) Met SNP was performed using the Taqman 5'nuclease assay. RESULTS: Our studies revealed that, in homozygous carriers of Met, but not Val alleles, the activity of COMT and MSR was significantly correlated throughout all tested brain regions. CONCLUSION: These results suggest that the reduced enzymatic activity of Met-containing COMT may be secondary to Met sulphoxidation and point to MSR as a key molecular determinant for the modulation of COMT activity.
AIMS: The enzyme catechol-O-methyltransferase (COMT) plays a primary role in the metabolism of catecholamine neurotransmitters and is implicated in the modulation of cognitive and emotional responses. The best characterized single nucleotide polymorphism (SNP) of the COMT gene consists of a valine (Val)-to-methionine (Met) substitution at codon 108/158. The Met-containing variant confers a marked reduction in COMT catalytic activity. We recently showed that the activity of recombinant COMT is positively regulated by the enzyme Met sulphoxide reductase (MSR), which counters the oxidation of Met residues of proteins. The current study was designed to assess whether brain COMT activity may be correlated to MSR in an allele-dependent fashion. METHODS:COMT and MSR activities were measured from post-mortem samples of prefrontal cortices, striata and cerebella of 32 subjects by using catechol and dabsyl-Met sulphoxide as substrates, respectively. Allelic discrimination of COMTVal(108/185) Met SNP was performed using the Taqman 5'nuclease assay. RESULTS: Our studies revealed that, in homozygous carriers of Met, but not Val alleles, the activity of COMT and MSR was significantly correlated throughout all tested brain regions. CONCLUSION: These results suggest that the reduced enzymatic activity of Met-containing COMT may be secondary to Met sulphoxidation and point to MSR as a key molecular determinant for the modulation of COMT activity.
Authors: Giuseppe Blasi; Venkata S Mattay; Alessandro Bertolino; Brita Elvevåg; Joseph H Callicott; Saumitra Das; Bhaskar S Kolachana; Michael F Egan; Terry E Goldberg; Daniel R Weinberger Journal: J Neurosci Date: 2005-05-18 Impact factor: 6.167
Authors: B Gutiérrez; J Bertranpetit; R Guillamat; V Vallès; M J Arranz; R Kerwin; L Fañanás Journal: Am J Psychiatry Date: 1997-01 Impact factor: 18.112
Authors: Barbara Schneider; Konrad Maurer; Dieter Sargk; Harald Heiskel; Bernhard Weber; Lutz Frölich; Klaus Georgi; Jürgen Fritze; Andreas Seidler Journal: Psychiatry Res Date: 2004-06-30 Impact factor: 3.222
Authors: G Kirov; K C Murphy; M J Arranz; I Jones; F McCandles; H Kunugi; R M Murray; P McGuffin; D A Collier; M J Owen; N Craddock Journal: Mol Psychiatry Date: 1998-07 Impact factor: 15.992
Authors: H Kunugi; H P Vallada; F Hoda; G Kirov; M Gill; K J Aitchison; D Ball; M J Arranz; R M Murray; D A Collier Journal: Biol Psychiatry Date: 1997-08-15 Impact factor: 13.382
Authors: Marco Bortolato; Consuelo Walss-Bass; Peter M Thompson; Jackob Moskovitz Journal: World J Biol Psychiatry Date: 2016-07-26 Impact factor: 4.132
Authors: T D Nascimento; N Yang; D Salman; H Jassar; N Kaciroti; E Bellile; T Danciu; R Koeppe; C Stohler; J K Zubieta; V Ellingrod; A F DaSilva Journal: J Dent Res Date: 2019-09-06 Impact factor: 8.924